Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s stock price fell 1.7% during mid-day trading on Monday . The stock traded as low as $10.70 and last traded at $11.24. 1,354,564 shares changed hands during mid-day trading, an increase of 301% from the average session volume of 337,931 shares. The stock had previously closed at $11.43.
Silverback Therapeutics Stock Down 1.7 %
The business has a fifty day simple moving average of $12.85 and a 200 day simple moving average of $12.66. The company has a market cap of $405.29 million, a price-to-earnings ratio of -4.64 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
- Five stocks we like better than Silverback Therapeutics
- What to Know About Investing in Penny Stocks
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How Investors Can Find the Best Cheap Dividend Stocks
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
